PT2215047E - Processo para o tratamento da deficiência de vitamina b12 - Google Patents

Processo para o tratamento da deficiência de vitamina b12 Download PDF

Info

Publication number
PT2215047E
PT2215047E PT88446737T PT08844673T PT2215047E PT 2215047 E PT2215047 E PT 2215047E PT 88446737 T PT88446737 T PT 88446737T PT 08844673 T PT08844673 T PT 08844673T PT 2215047 E PT2215047 E PT 2215047E
Authority
PT
Portugal
Prior art keywords
deficiency
treating vitamin
vitamin
treating
Prior art date
Application number
PT88446737T
Other languages
English (en)
Portuguese (pt)
Inventor
Cristina Castelli
Laura Kragie
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2215047(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of PT2215047E publication Critical patent/PT2215047E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT88446737T 2007-11-02 2008-10-31 Processo para o tratamento da deficiência de vitamina b12 PT2215047E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US2010808P 2008-01-09 2008-01-09
US8356608P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
PT2215047E true PT2215047E (pt) 2014-01-20

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88446737T PT2215047E (pt) 2007-11-02 2008-10-31 Processo para o tratamento da deficiência de vitamina b12

Country Status (18)

Country Link
US (3) US8022048B2 (https=)
EP (1) EP2215047B1 (https=)
JP (1) JP5555634B2 (https=)
KR (1) KR101344369B1 (https=)
CN (1) CN101952241B (https=)
AU (1) AU2008318423B2 (https=)
BR (1) BRPI0817396C8 (https=)
CA (1) CA2704780C (https=)
CL (1) CL2010000434A1 (https=)
CO (1) CO6280475A2 (https=)
DK (1) DK2215047T3 (https=)
ES (1) ES2443817T3 (https=)
MX (1) MX2010004716A (https=)
NZ (1) NZ585080A (https=)
PL (1) PL2215047T3 (https=)
PT (1) PT2215047E (https=)
RU (1) RU2469728C2 (https=)
WO (1) WO2009059188A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2461803B1 (en) * 2009-08-03 2018-10-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
CA2790708A1 (en) * 2010-02-24 2011-09-01 Emisphere Technologies, Inc. Oral b12 therapy
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
EP3542790B1 (en) 2012-03-22 2023-09-13 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
EP3928776B1 (en) 2016-04-22 2025-11-12 Spoke Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
MX2020003330A (es) * 2017-10-05 2020-07-28 Receptor Holdings Inc Composiciones de hierbas con mejor biodisponibilidad.
CA3078549A1 (en) * 2017-10-05 2019-04-11 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
AU2019385420A1 (en) 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
WO1998011900A2 (en) * 1996-09-18 1998-03-26 Sarill William J Compositions containing cobalamin and amino acids
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2002533399A (ja) 1998-12-28 2002-10-08 アラジー リミテッド エルエルシー アレルギー性疾患に対するシアノコバラミン（ビタミンｂ１２）の治療方法
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
EP1175390B1 (en) * 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
ES2386263T3 (es) 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
PL211976B1 (pl) 2001-06-01 2012-07-31 Novartis Ag Kompozycja farmaceutyczna do podawania doustnego oraz zastosowanie kompozycji
EP1420827B8 (en) 2001-08-17 2009-12-23 Novartis AG 5-cnac as oral delivery agent for parathyroid hormone fragments
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (es) 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
EP1545477A4 (en) * 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
WO2004087640A1 (en) 2003-04-04 2004-10-14 Dsm Ip Assets B.V. Process for the manufacture of n-alkoxalyl-alaninates
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
US20070155664A1 (en) 2003-07-04 2007-07-05 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
ES2330638T3 (es) 2003-07-11 2009-12-14 Novartis Ag Composiciones farmaceuticas dosificadas en forma oral que contienen un agente de suministro en forma micronizada.
MXPA06000807A (es) 2003-07-23 2006-08-23 Novartis Ag Uso de calcitonina en osteoartritis.
CN102001962B (zh) 2004-05-06 2013-04-03 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
MX2007001348A (es) * 2004-08-02 2008-03-11 Bebaas Inc Composiciones de vitamina b12.
WO2006124047A2 (en) 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
EP1948159A4 (en) 2005-11-04 2011-10-12 Genta Inc PHARMACEUTICAL COMPOSITIONS OF GALLIUM AND METHODS

Also Published As

Publication number Publication date
HK1146480A1 (en) 2011-06-10
RU2469728C2 (ru) 2012-12-20
CA2704780A1 (en) 2009-05-07
US8288360B2 (en) 2012-10-16
EP2215047B1 (en) 2013-11-20
BRPI0817396A2 (pt) 2015-04-07
US20100016255A1 (en) 2010-01-21
DK2215047T3 (da) 2014-02-03
CO6280475A2 (es) 2011-05-20
AU2008318423B2 (en) 2013-12-05
MX2010004716A (es) 2010-12-17
US20110293589A1 (en) 2011-12-01
JP5555634B2 (ja) 2014-07-23
ES2443817T3 (es) 2014-02-20
KR101344369B1 (ko) 2013-12-24
KR20100126263A (ko) 2010-12-01
CN101952241B (zh) 2014-06-11
WO2009059188A1 (en) 2009-05-07
BRPI0817396C8 (pt) 2021-05-25
PL2215047T3 (pl) 2014-05-30
AU2008318423A1 (en) 2009-05-07
US20130040910A1 (en) 2013-02-14
BRPI0817396B1 (pt) 2019-04-24
RU2010118423A (ru) 2011-12-10
NZ585080A (en) 2012-05-25
CL2010000434A1 (es) 2011-01-28
JP2011502997A (ja) 2011-01-27
EP2215047A1 (en) 2010-08-11
US8022048B2 (en) 2011-09-20
BRPI0817396B8 (pt) 2020-02-04
US8557792B2 (en) 2013-10-15
CN101952241A (zh) 2011-01-19
BRPI0817396C1 (pt) 2020-11-17
EP2215047A4 (en) 2010-11-10
CA2704780C (en) 2014-06-10

Similar Documents

Publication Publication Date Title
PL2215047T3 (pl) Sposób leczenia niedoborów witaminy b12
PL2148684T3 (pl) Sposób leczenia niedoboru i deficytu witaminy D
IL257418A (en) Methods for treating addiction
IL212348A0 (en) Treatment method
EP2313103A4 (en) PROCESS FOR TREATING A BLÉPHARITE
IL227641A0 (en) Methods for treating arthritis
ZA201707693B (en) Vitamin d3 and analogs thereof for treating alopecia
EP2032131A4 (en) Methods of Treatment
EP2148685A4 (en) METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D
PL2301893T3 (pl) Sposób oczyszczania ścieku
ZA200905974B (en) Stabilization of vitamin b12
EP2144504A4 (en) METHOD FOR COMBATING BRAIN CANCER
IL200769A (en) A method for processing potash
IL238394A0 (en) Cancer treatment method
GB0718684D0 (en) Treatment method
PT2393758E (pt) Processo de tratamento de águas residuais
EP2144886A4 (en) METHOD OF TREATING MELANOMA
EP2164515A4 (en) PROCESS FOR TREATING ATOPIC ECZEMA
PT2509599E (pt) Processo para o tratamento de cancro pancreático
EP2203432A4 (en) PROCESSING METHOD
GB0723972D0 (en) Use of vitamin B12
GB0717337D0 (en) Method of treatment
GB0711228D0 (en) Treatment method
ZA201102198B (en) Treatment method
GB0823435D0 (en) Method of treatment